Compare Novavax Inc (NVAX) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Unity Software Inc — how do they compare? Novavax Inc trades at $11.11 (market cap $1.82B), while Unity Software Inc trades at $46.24 (market cap $20.20B). The key difference: Unity Software Inc is far larger — about 11.1× Novavax Inc's market cap, and Unity Software Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Unity Software Inc for 50 Days on average.
| NVAX | U | |
|---|---|---|
Market Cap | $1.82B | $20.20B |
Volume | 6,198,505 | 15,432,191 |
Sector | Health | Technology |
52-Week High | $12.56 | $49.47 |
52-Week Low | $6.22 | $17.13 |
Typical Hold Time | 59 Days | 50 Days |
Enterprise Value | $1.39B | $20.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Unity Software (U) trades at $45.44, up 1.09% with bullish technical momentum and strong analyst support. The stock shows improving fundamentals with revenue stabilizing around $1.8B and narrowing losses, though profitability remains negative. Recent news highlights Meta VR partnership driving investor optimism, with technical indicators showing the stock testing resistance near $46.
Unity presents a growth story with improving cash flow and strategic partnerships, but faces execution risks amid persistent losses. With 82% analyst buy ratings and a $46.54 price target, Wall Street sees upside potential, though investors must weigh high valuation multiples against the company's path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
